<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9809671</journal-id>
<journal-id journal-id-type="pubmed-jr-id">21092</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Nature neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1097-6256</issn>
<issn pub-type="epub">1546-1726</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26713746</article-id>
<article-id pub-id-type="pmc">4966160</article-id>
<article-id pub-id-type="doi">10.1038/nn.4184</article-id>
<article-id pub-id-type="manuscript">NIHMS803695</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glia as drivers of abnormal neuronal activity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Robel</surname>
<given-names>Stefanie</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sontheimer</surname>
<given-names>Harald</given-names>
</name>
</contrib>
<aff id="A1">Virginia Tech Carilion Research Institute, Glial Biology in Health, Disease, and Cancer Center, Roanoke, Virginia, USA</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Correspondence should be addressed to H.S. (<email>sontheimer@vt.edu</email>)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>7</month>
<year>2016</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>28</fpage>
<lpage>33</lpage>
<!--elocation-id from pubmed: 10.1038/nn.4184-->
<permissions>
<license license-type="permissions-link">
<license-p>Reprints and permissions information is available online at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/reprints/index.html">http://www.nature.com/reprints/index.html</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Reactive astrocytes have been proposed to become incompetent bystanders in epilepsy as a result of cellular changes rendering them unable to perform important housekeeping functions. Indeed, successful surgical treatment of mesiotemporal lobe epilepsy hinges on the removal of the glial scar. New research now extends the role of astrocytes, suggesting that they may drive the disease process by impairing the inhibitory action of neuronal GABA receptors. Here we discuss studies that include hyperexcitability resulting from impaired supply of astrocytic glutamine for neuronal GABA synthesis, and epilepsy resulting from genetically induced astrogliosis or malignant transformation, both of which render the inhibitory neurotransmitter GABA excitatory. In these examples, glial cells alter the expression or function of neuronal proteins involved in excitability. Although epilepsy has traditionally been thought of as a disease caused by changes in neuronal properties exclusively, these new findings challenge us to consider the contribution of glial cells as drivers of epileptogenesis in acquired epilepsies.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>